Advanced search in
Projects
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
7 Projects, page 1 of 1

  • Canada
  • 2012-2021
  • 2016
  • 2022

  • Open Access mandate for Publications
    Funder: EC Project Code: 723770
    Overall Budget: 15,270,000 EURFunder Contribution: 5,039,100 EUR
    Partners: SFI, STW, BMBF, TÜBİTAK, ETAg, Ministry of Education, SAV, FRS FNRS, THE RESEARCH COUNCIL OF NORWAY, FCT...

    Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.

  • Open Access mandate for Publications
    Funder: EC Project Code: 696295
    Overall Budget: 14,403,800 EURFunder Contribution: 4,753,240 EUR
    Partners: DEPARTMENT OF AGRICULTURE, FOOD AND THE MARINE, SFI, DLR, STATE RESEARCH AGENCY OF SPAIN, MIUR, MCI, NCBR, SPW, ANR, Ministry of Education...

    ERA-HDHL is a proposal of ERA-NET Cofund in the field of nutrition and health to support the Joint Programme Initiative Healthy Diet for a Healthy Life (JPI HDHL). Nowadays, there is a high burden of non-communicable diseases due to unhealthy diet and lifestyle patterns. The 24 members of the JPI HDHL are working together to develop means to (1) motivate people to adopt healthier lifestyles including dietary choices and physical activity, (2) develop and produce healthy, high-quality, safe and sustainable foods and (3) prevent diet-related diseases. Between 2012 and 2015, JPI HDHL had implemented 7 JFAs with 40 M€ funds from national funding. The JPI HDHL is now set for further enhancement in tight coordination with the EC through the ERA-NET Cofund instrument. ERA-HDHL will provide a robust platform for implementing joint funding actions (JFAs) that address the needs identified in the JPI HDHL strategic research agenda and strengthen the research funding activities of JPI HDHL. An EC cofunded call on the identification and validation of biomarkers in nutrition and health will be implemented. For this foreseen action, the member countries of the JPI HDHL have doubled their financial commitment comparing to previous JFA implemented on a similar topic. Moreover, ERA-HDHL will launch at least 3 additional JFAs in line to fulfil the JPI HDHL objectives.

  • Funder: NIH Project Code: 5R01HD089713-05
    Funder Contribution: 124,763 USD
    Partners: UBC
  • Funder: UKRI Project Code: MR/N005759/1
    Funder Contribution: 3,039,500 GBP
    Partners: McMaster University

    Cardiovascular disease is a leading cause of death globally estimated to be responsible for approximately 17 million deaths annually. Heart disease and stroke account for nearly one third of all deaths and are a major cause of hospitalization. Patients with congestive heart failure (CHF) are at particularly high risk. Clinical trials demonstrate that nearly one third of patients with CHF will experience a myocardial infarction (MI), stroke, or hospitalization for CHF. Observational studies have established an association between influenza infection and major adverse vascular events . It follows that vaccinating such a high risk group as patients with CHF against influenza may prevent adverse vascular events. However, these studies are subject to bias and a well designed clinical trial is needed to test the effect of influenza vaccination on preventing adverse vascular events. The goal of this study is to assess whether inactivated influenza vaccine can reduce adverse vascular events in high risk participants. We will address the question by randomizing patients at high risk for adverse vascular events to either annual inactivated influenza vaccine or to placebo over three influenza seasons. The primary outcome is a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), non- fatal stroke, and hospitalization for CHF. We will enroll 3,500 participants from centres in seven countries: Philippines (the lead centre), Mozambique, Sudan, Uganda, Saudi Arabia, Malaysia, China. This proposed randomized trial has important implications for the management of patients at high risk for major adverse vascular events. Although the influenza vaccine is recommended annually for groups with diabetes and cardiovascular disease in many counties, uptake of these recommendations is relatively low. Cardiologists in most jurisdictions do not routinely recommend annual influenza vaccine for their patients as a strategy to reduce future adverse vascular events such as acute coronary syndrome or stroke. Uptake of influenza vaccine in patients with heart disease varies by country but in INTER-CHF sites (where are trial will be conducted) is 11% on average. Rigorous demonstration of influenza vaccine leading to a reduction in major adverse vascular events would represent a landmark study. We anticipate that such a trial would influence management decisions by physicians for patients at high risk for major vascular events. The effect size we propose testing is comparable to secondary prevention strategies available and given the fact that a vaccine is given once annually it is simple and inexpensive. Given the large burden of disease, the possibility to reduce cardiovascular and stroke related death is a compelling argument for this trial. If influenza vaccine is shown to reduce adverse vascular events, it will represent an important change in how prevention of adverse vascular events is thought about. The fact that our primary outcome is a composite, including various forms of vascular disease will increase generalizability. The study would be a milestone in contributing to evidence-based clinical as well public health policy.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 727890
    Overall Budget: 15,490,100 EURFunder Contribution: 15,490,100 EUR
    Partners: UH, NUIM, IMR, CNRS, DTU, STIFTELSEN NANSEN SENTER FOR MILJOOG FJERNMALING, AU, NIERSC, UPM, ROIS...

    The overall objective of INTAROS is to develop an integrated Arctic Observation System (iAOS) by extending, improving and unifying existing systems in the different regions of the Arctic. INTAROS will have a strong multidisciplinary focus, with tools for integration of data from atmosphere, ocean, cryosphere and terrestrial sciences, provided by institutions in Europe, North America and Asia. Satellite earth observation data plays an increasingly important role in such observing systems, because the amount of EO data for observing the global climate and environment grows year by year. In situ observing systems are much more limited due to logistical constraints and cost limitations. The sparseness of in situ data is therefore the largest gap in the overall observing system. INTAROS will assess strengths and weaknesses of existing observing systems and contribute with innovative solutions to fill some of the critical gaps in the in situ observing network. INTAROS will develop a platform, iAOS, to search for and access data from distributed databases. The evolution into a sustainable Arctic observing system requires coordination, mobilization and cooperation between the existing European and international infrastructures (in-situ and remote including space-based), the modeling communities and relevant stakeholder groups. INTAROS will include development of community-based observing systems, where local knowledge is merged with scientific data. An integrated Arctic Observation System will enable better-informed decisions and better-documented processes within key sectors (e.g. local communities, shipping, tourism, fisheries), in order to strengthen the societal and economic role of the Arctic region and support the EU strategy for the Arctic and related maritime and environmental policies.

  • Open Access mandate for Publications
    Funder: EC Project Code: 680966
    Overall Budget: 20,882,200 EURFunder Contribution: 6,772,340 EUR
    Partners: NCBR, ISCIII, MINECO, Academy of Finland, ANR, VIAA, FFWF, CSO-MOH, UKRI, MRC...

    The ERA-NET NEURON Cofund will coordinate and align European and international research funding programmes in the area of brain-related diseases and disorders of the nervous system. Key activity is the implementation of an EC co-funded joint transnational call for research proposals. The mission of NEURON is based on the fact that disorders of the brain are the major cause for impaired quality of life, and they are a heavy burden not only for patients, their families and carers, but also a socioeconomic problem for society. By improving collaboration and by implementing a variety of additional activities (such as further joint transnational calls and support of early-career scientists) NEURON Cofund will decrease fragmentation of research programmes and improve the funding situation for neuroscience researchers thereby strengthening the search for novel therapeutic approaches to fight brain disease; NEURON Cofund will also develop and provide concrete plans for (i) expanding data sharing, (ii) promoting common data elements for the establishment of patient registries, and (iii) involving stakeholders and relevant existing initiatives such as patient organizations. The aforementioned challenges will be addressed in a network of 22 funding organizations across 14 European Member and Associated States and Third countries.

  • Funder: UKRI Project Code: EP/N017188/1
    Funder Contribution: 5,296,040 GBP
    Partners: University of Cambridge, University of Waterloo (Canada), Private Address, CDT, Amadeus Capital Partners Limited, University of Oxford, UQ, Oxford Nanopore Technologies (United Kingdom), IBM Research GmbH, Oxford Instruments plc...

    Put your hand under a working laptop computer and you'll find that it's warm, due to the heat produced by the transistors in it. This isn't just a problem for your own computer: nearly 5% of the world's electricity is used by computers and the internet, a figure expected to double over the next decade. Much of this is wasted in generating heat that, according to thermodynamic theory, is not needed for information processing; and over half is for cooling systems to remove the unwanted heat. The resulting carbon emissions are comparable to the total global aviation industry. If we can reduce the energy consumption of logic operations in information technologies, or scavenge just a fraction of the waste heat, the effect on energy use and carbon emissions could be vast. Recent research breakthroughs have opened up new possibilities for making tiny electronic components and circuits, based on individual molecules, which have the potential to do just that (since their behaviour is not constrained by the laws of classical physics). To make this a reality, we must first learn to understand and control quantum effects in electronic nanodevices. We can use a new material, graphene, to make mechanically and chemically stable electrodes and connect them to electrically-active molecules. New methods allow us to make a very small gap in graphene which is just the right size for a molecule or a single strand of DNA (for fast and cheap DNA sequencing). Chemical units have been developed that attach to molecules and adhere like sticky notes to the graphene contacts on each side of the gap.. With graphene electrodes we can also make magnetic connections to single molecules to create molecular memory devices. A phenomenon called quantum interference can dramatically affect the flow of electric current in molecules. Harnessing these quantum effects will enable us to make tiny switches that would consume very little energy, and to generate electricity from small differences in temperature. The time is ripe for a focused research effort, drawing together these advances to transform our understanding and to pave the way for practical applications. Our programme is one of discovery science with a view to practical benefit. QuEEN will first establish the basic platform technology for experiments on single-molecule devices, including selection of the best molecules and control of their quantum interference by a local electric field. It will conclude by seeking to transfer results from rather ideal (cryogenic) laboratory conditions to a real-world environment, at room temperature. In between those two challenges, we shall explore three particularly promising areas for scientific discovery and application: controlling the magnetic property of an electron, known as spin, for quantum interference for potential use in universal computer memories; seeing how much electricity a molecule can generate if its ends are held at different temperatures, offering the potential for energy harvesting; and finding the performance limits of a single-molecule transistor, for potential uses in low-power computing and timer-controllers for the Internet of Things. The research requires four core skill sets, which form a virtuous circle: chemistry, to design and synthesise the molecules at the heart of our devices and stick them reliably to electrodes; nanofabrication, to make molecule-sized gaps in graphene ribbons; measurement techniques and advanced instrumentation to control the environment and characterise the quantum effects; and theory, to predict the effects, screen potential molecules, and interpret the results. QuEEN brings together a research team with exactly the right mix of expertise; an Advisory Board with wide experience of successful technological entrepreneurship; and a group of industrial partners who will not only shape and assist with the research but also provide a pathway to technological innovation and real-world applications.

Advanced search in
Projects
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
7 Projects, page 1 of 1
  • Open Access mandate for Publications
    Funder: EC Project Code: 723770
    Overall Budget: 15,270,000 EURFunder Contribution: 5,039,100 EUR
    Partners: SFI, STW, BMBF, TÜBİTAK, ETAg, Ministry of Education, SAV, FRS FNRS, THE RESEARCH COUNCIL OF NORWAY, FCT...

    Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.

  • Open Access mandate for Publications
    Funder: EC Project Code: 696295
    Overall Budget: 14,403,800 EURFunder Contribution: 4,753,240 EUR
    Partners: DEPARTMENT OF AGRICULTURE, FOOD AND THE MARINE, SFI, DLR, STATE RESEARCH AGENCY OF SPAIN, MIUR, MCI, NCBR, SPW, ANR, Ministry of Education...

    ERA-HDHL is a proposal of ERA-NET Cofund in the field of nutrition and health to support the Joint Programme Initiative Healthy Diet for a Healthy Life (JPI HDHL). Nowadays, there is a high burden of non-communicable diseases due to unhealthy diet and lifestyle patterns. The 24 members of the JPI HDHL are working together to develop means to (1) motivate people to adopt healthier lifestyles including dietary choices and physical activity, (2) develop and produce healthy, high-quality, safe and sustainable foods and (3) prevent diet-related diseases. Between 2012 and 2015, JPI HDHL had implemented 7 JFAs with 40 M€ funds from national funding. The JPI HDHL is now set for further enhancement in tight coordination with the EC through the ERA-NET Cofund instrument. ERA-HDHL will provide a robust platform for implementing joint funding actions (JFAs) that address the needs identified in the JPI HDHL strategic research agenda and strengthen the research funding activities of JPI HDHL. An EC cofunded call on the identification and validation of biomarkers in nutrition and health will be implemented. For this foreseen action, the member countries of the JPI HDHL have doubled their financial commitment comparing to previous JFA implemented on a similar topic. Moreover, ERA-HDHL will launch at least 3 additional JFAs in line to fulfil the JPI HDHL objectives.

  • Funder: NIH Project Code: 5R01HD089713-05
    Funder Contribution: 124,763 USD
    Partners: UBC
  • Funder: UKRI Project Code: MR/N005759/1
    Funder Contribution: 3,039,500 GBP
    Partners: McMaster University

    Cardiovascular disease is a leading cause of death globally estimated to be responsible for approximately 17 million deaths annually. Heart disease and stroke account for nearly one third of all deaths and are a major cause of hospitalization. Patients with congestive heart failure (CHF) are at particularly high risk. Clinical trials demonstrate that nearly one third of patients with CHF will experience a myocardial infarction (MI), stroke, or hospitalization for CHF. Observational studies have established an association between influenza infection and major adverse vascular events . It follows that vaccinating such a high risk group as patients with CHF against influenza may prevent adverse vascular events. However, these studies are subject to bias and a well designed clinical trial is needed to test the effect of influenza vaccination on preventing adverse vascular events. The goal of this study is to assess whether inactivated influenza vaccine can reduce adverse vascular events in high risk participants. We will address the question by randomizing patients at high risk for adverse vascular events to either annual inactivated influenza vaccine or to placebo over three influenza seasons. The primary outcome is a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), non- fatal stroke, and hospitalization for CHF. We will enroll 3,500 participants from centres in seven countries: Philippines (the lead centre), Mozambique, Sudan, Uganda, Saudi Arabia, Malaysia, China. This proposed randomized trial has important implications for the management of patients at high risk for major adverse vascular events. Although the influenza vaccine is recommended annually for groups with diabetes and cardiovascular disease in many counties, uptake of these recommendations is relatively low. Cardiologists in most jurisdictions do not routinely recommend annual influenza vaccine for their patients as a strategy to reduce future adverse vascular events such as acute coronary syndrome or stroke. Uptake of influenza vaccine in patients with heart disease varies by country but in INTER-CHF sites (where are trial will be conducted) is 11% on average. Rigorous demonstration of influenza vaccine leading to a reduction in major adverse vascular events would represent a landmark study. We anticipate that such a trial would influence management decisions by physicians for patients at high risk for major vascular events. The effect size we propose testing is comparable to secondary prevention strategies available and given the fact that a vaccine is given once annually it is simple and inexpensive. Given the large burden of disease, the possibility to reduce cardiovascular and stroke related death is a compelling argument for this trial. If influenza vaccine is shown to reduce adverse vascular events, it will represent an important change in how prevention of adverse vascular events is thought about. The fact that our primary outcome is a composite, including various forms of vascular disease will increase generalizability. The study would be a milestone in contributing to evidence-based clinical as well public health policy.

  • Open Access mandate for Publications and Research data
    Funder: EC Project Code: 727890
    Overall Budget: 15,490,100 EURFunder Contribution: 15,490,100 EUR
    Partners: UH, NUIM, IMR, CNRS, DTU, STIFTELSEN NANSEN SENTER FOR MILJOOG FJERNMALING, AU, NIERSC, UPM, ROIS...

    The overall objective of INTAROS is to develop an integrated Arctic Observation System (iAOS) by extending, improving and unifying existing systems in the different regions of the Arctic. INTAROS will have a strong multidisciplinary focus, with tools for integration of data from atmosphere, ocean, cryosphere and terrestrial sciences, provided by institutions in Europe, North America and Asia. Satellite earth observation data plays an increasingly important role in such observing systems, because the amount of EO data for observing the global climate and environment grows year by year. In situ observing systems are much more limited due to logistical constraints and cost limitations. The sparseness of in situ data is therefore the largest gap in the overall observing system. INTAROS will assess strengths and weaknesses of existing observing systems and contribute with innovative solutions to fill some of the critical gaps in the in situ observing network. INTAROS will develop a platform, iAOS, to search for and access data from distributed databases. The evolution into a sustainable Arctic observing system requires coordination, mobilization and cooperation between the existing European and international infrastructures (in-situ and remote including space-based), the modeling communities and relevant stakeholder groups. INTAROS will include development of community-based observing systems, where local knowledge is merged with scientific data. An integrated Arctic Observation System will enable better-informed decisions and better-documented processes within key sectors (e.g. local communities, shipping, tourism, fisheries), in order to strengthen the societal and economic role of the Arctic region and support the EU strategy for the Arctic and related maritime and environmental policies.

  • Open Access mandate for Publications
    Funder: EC Project Code: 680966
    Overall Budget: 20,882,200 EURFunder Contribution: 6,772,340 EUR
    Partners: NCBR, ISCIII, MINECO, Academy of Finland, ANR, VIAA, FFWF, CSO-MOH, UKRI, MRC...

    The ERA-NET NEURON Cofund will coordinate and align European and international research funding programmes in the area of brain-related diseases and disorders of the nervous system. Key activity is the implementation of an EC co-funded joint transnational call for research proposals. The mission of NEURON is based on the fact that disorders of the brain are the major cause for impaired quality of life, and they are a heavy burden not only for patients, their families and carers, but also a socioeconomic problem for society. By improving collaboration and by implementing a variety of additional activities (such as further joint transnational calls and support of early-career scientists) NEURON Cofund will decrease fragmentation of research programmes and improve the funding situation for neuroscience researchers thereby strengthening the search for novel therapeutic approaches to fight brain disease; NEURON Cofund will also develop and provide concrete plans for (i) expanding data sharing, (ii) promoting common data elements for the establishment of patient registries, and (iii) involving stakeholders and relevant existing initiatives such as patient organizations. The aforementioned challenges will be addressed in a network of 22 funding organizations across 14 European Member and Associated States and Third countries.

  • Funder: UKRI Project Code: EP/N017188/1
    Funder Contribution: 5,296,040 GBP
    Partners: University of Cambridge, University of Waterloo (Canada), Private Address, CDT, Amadeus Capital Partners Limited, University of Oxford, UQ, Oxford Nanopore Technologies (United Kingdom), IBM Research GmbH, Oxford Instruments plc...

    Put your hand under a working laptop computer and you'll find that it's warm, due to the heat produced by the transistors in it. This isn't just a problem for your own computer: nearly 5% of the world's electricity is used by computers and the internet, a figure expected to double over the next decade. Much of this is wasted in generating heat that, according to thermodynamic theory, is not needed for information processing; and over half is for cooling systems to remove the unwanted heat. The resulting carbon emissions are comparable to the total global aviation industry. If we can reduce the energy consumption of logic operations in information technologies, or scavenge just a fraction of the waste heat, the effect on energy use and carbon emissions could be vast. Recent research breakthroughs have opened up new possibilities for making tiny electronic components and circuits, based on individual molecules, which have the potential to do just that (since their behaviour is not constrained by the laws of classical physics). To make this a reality, we must first learn to understand and control quantum effects in electronic nanodevices. We can use a new material, graphene, to make mechanically and chemically stable electrodes and connect them to electrically-active molecules. New methods allow us to make a very small gap in graphene which is just the right size for a molecule or a single strand of DNA (for fast and cheap DNA sequencing). Chemical units have been developed that attach to molecules and adhere like sticky notes to the graphene contacts on each side of the gap.. With graphene electrodes we can also make magnetic connections to single molecules to create molecular memory devices. A phenomenon called quantum interference can dramatically affect the flow of electric current in molecules. Harnessing these quantum effects will enable us to make tiny switches that would consume very little energy, and to generate electricity from small differences in temperature. The time is ripe for a focused research effort, drawing together these advances to transform our understanding and to pave the way for practical applications. Our programme is one of discovery science with a view to practical benefit. QuEEN will first establish the basic platform technology for experiments on single-molecule devices, including selection of the best molecules and control of their quantum interference by a local electric field. It will conclude by seeking to transfer results from rather ideal (cryogenic) laboratory conditions to a real-world environment, at room temperature. In between those two challenges, we shall explore three particularly promising areas for scientific discovery and application: controlling the magnetic property of an electron, known as spin, for quantum interference for potential use in universal computer memories; seeing how much electricity a molecule can generate if its ends are held at different temperatures, offering the potential for energy harvesting; and finding the performance limits of a single-molecule transistor, for potential uses in low-power computing and timer-controllers for the Internet of Things. The research requires four core skill sets, which form a virtuous circle: chemistry, to design and synthesise the molecules at the heart of our devices and stick them reliably to electrodes; nanofabrication, to make molecule-sized gaps in graphene ribbons; measurement techniques and advanced instrumentation to control the environment and characterise the quantum effects; and theory, to predict the effects, screen potential molecules, and interpret the results. QuEEN brings together a research team with exactly the right mix of expertise; an Advisory Board with wide experience of successful technological entrepreneurship; and a group of industrial partners who will not only shape and assist with the research but also provide a pathway to technological innovation and real-world applications.